Clinical Trials Browser

Withdrawn × Neoplasms, Plasma Cell × Dexamethasone × Clear all

NCT01647165 2019-12-12

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01501370 2016-05-10

ZLd_Ld

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell